Legal & General Group
TVTX icon

Legal & General Group’s Travere Therapeutics TVTX Stock Holding History

Legal & General Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.4M Sell
451,056
-85,869
-16% -$2.57M ﹤0.01% 988
2025
Q4 		$20.5M Buy
536,925
+16,333
+3% +$531K ﹤0.01% 835
2025
Q3 		$12.4M Buy
520,592
+10,164
+2% +$191K ﹤0.01% 1088
2025
Q2 		$7.55M Buy
510,428
+97,496
+24% +$1.62M ﹤0.01% 1350
2025
Q1 		$7.4M Buy
412,932
+333,969
+423% +$6.78M ﹤0.01% 1304
2024
Q4 		$1.38M Sell
78,963
-1,995
-2% -$35.3K ﹤0.01% 2133
2024
Q3 		$1.13M Buy
80,958
+6,718
+9% +$70K ﹤0.01% 2189
2024
Q2 		$610K Sell
74,240
-913
-1% -$6.15K ﹤0.01% 2349
2024
Q1 		$579K Sell
75,153
-59,699
-44% -$504K ﹤0.01% 2375
2023
Q4 		$1.21M Sell
134,852
-37,090
-22% -$270K ﹤0.01% 2145
2023
Q3 		$1.54M Buy
171,942
+36,404
+27% +$514K ﹤0.01% 2012
2023
Q2 		$2.08M Buy
135,538
+10,306
+8% +$187K ﹤0.01% 1911
2023
Q1 		$2.82M Buy
125,232
+49,939
+66% +$1.06M ﹤0.01% 1719
2022
Q4 		$1.58M Buy
75,293
+11,211
+17% +$238K ﹤0.01% 1978
2022
Q3 		$1.58M Buy
64,082
+41,481
+184% +$1.07M ﹤0.01% 1972
2022
Q2 		$548K Buy
22,601
+957
+4% +$24.1K ﹤0.01% 2317
2022
Q1 		$558K Buy
21,644
+298
+1% +$7.91K ﹤0.01% 2363
2021
Q4 		$663K Buy
21,346
+108
+0.5% +$3.04K ﹤0.01% 2334
2021
Q3 		$515K Buy
21,238
+10,816
+104% +$199K ﹤0.01% 2401
2021
Q2 		$152K Sell
10,422
-1,191
-10% -$23.5K ﹤0.01% 2610
2021
Q1 		$290K Buy
11,613
+1,718
+17% +$47.5K ﹤0.01% 2385
2020
Q4 		$270K Sell
9,895
-86
-0.9% -$2.01K ﹤0.01% 2366
2020
Q3 		$184K Sell
9,981
-66
-0.7% -$1.28K ﹤0.01% 2372
2020
Q2 		$205K Buy
10,047
+227
+2% +$3.61K ﹤0.01% 2359
2020
Q1 		$143K Sell
9,820
-24,378
-71% -$367K ﹤0.01% 2331
2019
Q4 		$486K Buy
34,198
+2,507
+8% +$32K ﹤0.01% 2224
2019
Q3 		$362K Buy
31,691
+12,058
+61% +$199K ﹤0.01% 2227
2019
Q2 		$394K Buy
19,633
+1,109
+6% +$21.9K ﹤0.01% 2189
2019
Q1 		$419K Buy
18,524
+2,658
+17% +$58.7K ﹤0.01% 2190
2018
Q4 		$360K Buy
15,866
+2,325
+17% +$57.8K ﹤0.01% 2192
2018
Q3 		$389K Buy
13,541
+3,395
+33% +$97K ﹤0.01% 2192
2018
Q2 		$277K Sell
10,146
-807
-7% -$21.5K ﹤0.01% 2242
2018
Q1 		$245K Buy
10,953
+902
+9% +$21.5K ﹤0.01% 2257
2017
Q4 		$214K Hold
10,051
– – ﹤0.01% 2296
2017
Q3 		$250K Buy
10,051
+1,387
+16% +$30.5K ﹤0.01% 2266
2017
Q2 		$168K Buy
8,664
+355
+4% +$6.44K ﹤0.01% 2367
2017
Q1 		$152K Sell
8,309
-133
-2% -$2.6K ﹤0.01% 2360
2016
Q4 		$161K Buy
8,442
+3,825
+83% +$78.2K ﹤0.01% 2319
2016
Q3 		$101K Sell
4,617
-1,728
-27% -$32.9K ﹤0.01% 2216
2016
Q2 		$112K Hold
6,345
– – ﹤0.01% 2027
2016
Q1 		$86K Buy
6,345
+1,867
+42% +$28.3K ﹤0.01% 2148
2015
Q4 		$88K Hold
4,478
– – ﹤0.01% 2150
2015
Q3 		$86K Buy
4,478
+479
+12% +$14.2K ﹤0.01% 2131
2015
Q2 		$130K Hold
3,999
– – ﹤0.01% 1946
2015
Q1 		$95K Hold
3,999
– – ﹤0.01% 2077
2014
Q4 		$48K Hold
3,999
– – ﹤0.01% 2453
2014
Q3 		$38K Buy
+3,999
New +$47K ﹤0.01% 2514

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Legal & General Group's TVTX Position: Q1 2026 in Review

Legal & General Group reduced its Travere Therapeutics (TVTX) stake by 16% in Q1 2026, selling an estimated $2.57M and leaving 451,056 shares worth $13.4M. The position accounts for ﹤0.01% of the portfolio, ranked #988.

Legal & General Group first reported a position in TVTX in Q3 2014 and has held it in 47 quarters since. The position peaked at $20.5M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Legal & General Group held 451,056 shares of Travere Therapeutics worth $13.4M as of Q1 2026.
  • Legal & General Group sold 85,869 Travere Therapeutics shares in Q1 2026, an estimated $2.57M.
  • Travere Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #988 holding.
  • Legal & General Group first reported a position in Travere Therapeutics in Q3 2014 and has held it in 47 quarters since.
  • Legal & General Group's Travere Therapeutics position peaked at $20.5M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.